SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

CADL

Candel Therapeutics Inc.
NASDAQHealth Care

Latest close: 8.19 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 11, 2026Reported sale · Form 4Paul Peter Tak, Chief Executive Officer · $620.9KOpen the filing ↗
  2. Sep 10, 2026Reported sale · Form 4Paul Peter Tak, Chief Executive Officer · $2.5MOpen the filing ↗
  3. Sep 10, 2026Notice of sale · Form 144PAUL PETER TAK · Director, Officer · $3.4MOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record39814 flagged findings
Reported transactions (Form 4)80since Jan 8, 2025 · and 4 other holdings
Corporate events (8-K)23since Jul 30, 2021

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-14share offering or dilution eventrecentOpen filing ↗
    “…additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s…”
    +1 more passage from the same document
    • “…OF COMMON STOCK SUBJECT TO WARRANTS EXERCISE PRICE PER SHARE EXPIRATION DATES Series B Warrants 3,672,484 $ 6.81 September 2027…”
  • 2026-03-12share offering or dilution eventrecentOpen filing ↗
    “…outstanding may increase substantially as a result of our November 2018 issuance of warrants to purchase up to an aggregate of…”
    +1 more passage from the same document
    • “…November 13, 2018 by and between the Company and PBM ADV Holdings, LLC (the Purchase Agreement) and the issuance of shares of the…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 398)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • Sep 10, 26Form 144 ↗Notice of proposed sale
  • Sep 10, 26Form 4 ↗Insider transaction
  • Sep 10, 26Form 3 ↗Insider transaction
  • Sep 10, 268-K ↗Current report · A senior executive left or was appointed
  • Sep 9, 268-K ↗Current report · Communication to the market
  • Aug 19, 26Form 4 ↗Insider transaction
  • Aug 17, 26Form 144 ↗Notice of proposed sale
  • Aug 13, 2610-Q ↗Quarterly report
  • Aug 13, 268-K ↗Current report · Results
  • Jul 27, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 6.6% · event on Jun 30, 26
  • Jul 8, 26Form 4 ↗Insider transaction
  • Jul 8, 26Form 3 ↗Insider transaction
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 2 Form 4 filingsshow all 2hide

398 filings on record, the oldest from Mar 15, 21.

Listing the 25 most recent filings of the 398 on record.

8-Ks, explained

Stress2Structure10Governance11
  • Sep 10, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 16, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Structure5 material agreements entered2025 – 2026show all 5hide
    • Feb 23, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Feb 19, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Oct 14, 25StructureEntered a material agreement+6 more in the same filing8-K 1.01 ↗
    • Aug 21, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Jun 24, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 23, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 6, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Dec 13, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jan 12, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Dec 15, 23GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Nov 28, 23StressRestructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
  • Nov 21, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Governance3 senior executive changes2022 – 2023show all 3hide
    • Jun 8, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Sep 7, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Aug 1, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Mar 1, 22StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗

2 older filings not shown

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Paul B Manning7.9%Dec 16, 24SCHEDULE 13D/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • FMR LLC15.0%Jan 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • RTW Investments, LP8.8%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.6.6%Jun 30, 26SCHEDULE 13G ↗2 earlier filings
  • Anders Hove5.2%Jun 25, 25SCHEDULE 13G ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • Baker Bros. Advisors LP5.0%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 10, PAUL PETER TAK filed notice of intent to sell up to $3.4M. That is about 0.37% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $3.2M across 2 trades, between Sep 10 and Sep 11, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+3 more recent notices · 3 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 11, 26Sell$621KPaul Peter TakChief Executive Officer↗
  • Sep 10, 26Sell$2.5MPaul Peter TakChief Executive Officer↗
  • Aug 17, 26Sell$84KSeshu TyagarajanChief Technology Officer↗
  • Jun 29, 26Sell$236KFrancesca BaroneChief Scientific Officer↗
  • Jun 29, 26Sell$70KSeshu TyagarajanChief Technology Officer↗
  • Feb 23, 26Buy$3.0MPaul B Manning↗
  • Jul 28, 25Sell$7KWilliam Garrett NicholsChief Medical Officer↗
  • Jun 30, 25Sell$4KWilliam Garrett NicholsChief Medical Officer↗
  • Mar 19, 25Sell$4KPaul Peter TakChief Executive Officer↗
  • Mar 18, 25Sell$226KPaul Peter TakChief Executive Officer↗
  • Mar 18, 25Sell$282KFrancesca BaroneChief Scientific Officer↗
  • Mar 18, 25Sell$397KWilliam Garrett NicholsChief Medical Officer↗

There are 9 more transactions in this stretch.

Stock compensation, tax and giftsshow the 19 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 10, 26Compensation$194KPaul Peter TakChief Executive Officer↗
  • Jul 28, 25Compensation$1KWilliam Garrett NicholsChief Medical Officer↗
  • Jun 30, 25Compensation$1KWilliam Garrett NicholsChief Medical Officer↗
  • Jun 25, 25Compensation$300KJOSEPH C PAPA↗
  • Jun 25, 25Compensation$25KGary J. Nabel↗
  • Jun 25, 25Compensation$25KCharles SchochChief Financial Officer↗
  • Jun 25, 25Compensation$20KFrancesca BaroneChief Scientific Officer↗
  • Jun 25, 25Compensation$10KNicoletta Loggia↗
  • Jun 25, 25Compensation$520KChristopher Martell↗
  • Jun 25, 25Compensation$5.0MPaul B Manning↗
  • Jun 25, 25Compensation$200KPaul Peter TakChief Executive Officer↗
  • Jun 25, 25Compensation$25KSeshu TyagarajanChief Technology Officer↗
  • Mar 18, 25Compensation$28KFrancesca BaroneChief Scientific Officer↗
  • Mar 18, 25Compensation$17KWilliam Garrett NicholsChief Medical Officer↗
  • Mar 18, 25Compensation$18KWilliam Garrett NicholsChief Medical Officer↗
  • Mar 17, 25Compensation$26KSeshu TyagarajanChief Technology Officer↗
  • Feb 21, 25Other$127KEstuardo Aguilar-Cordova↗
  • Feb 21, 25Other$127KEstuardo Aguilar-Cordova↗
  • Feb 10, 25Other$270KEstuardo Aguilar-Cordova↗

The full record holds 112 transactions and goes back to Dec 8, 22.

Its sector and its market

Candel Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Candel Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Candel Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
398 documents on file, from Mar 15, 2021 to Oct 2, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.